A retrospective review of multiple findings in diagnostic exome sequencing: half are distinct and half are overlapping diagnoses.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
10 2019
Historique:
received: 13 08 2018
accepted: 25 02 2019
pubmed: 22 3 2019
medline: 18 3 2020
entrez: 22 3 2019
Statut: ppublish

Résumé

We evaluated clinical and genetic features enriched in patients with multiple Mendelian conditions to determine which patients are more likely to have multiple potentially relevant genetic findings (MPRF). Results of the first 7698 patients who underwent exome sequencing at Ambry Genetics were reviewed. Clinical and genetic features were examined and degree of phenotypic overlap between the genetic diagnoses was evaluated. Among patients referred for exome sequencing, 2% had MPRF. MPRF were more common in patients from consanguineous families and patients with greater clinical complexity. The difference in average number of organ systems affected is small: 4.3 (multiple findings) vs. 3.9 (single finding) and may not be distinguished in clinic. Patients with multiple genetic diagnoses had a slightly higher number of organ systems affected than patients with single genetic diagnoses, largely because the comorbid conditions affected overlapping organ systems. Exome testing may be beneficial for all cases with multiple organ systems affected. The identification of multiple relevant genetic findings in 2% of exome patients highlights the utility of a comprehensive molecular workup and updated interpretation of existing genomic data; a single definitive molecular diagnosis from analysis of a limited number of genes may not be the end of a diagnostic odyssey.

Identifiants

pubmed: 30894705
doi: 10.1038/s41436-019-0477-2
pii: S1098-3600(21)04483-X
pmc: PMC6774997
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2199-2207

Références

Int J Breast Cancer. 2016;2016:2469523
pubmed: 27822389
Am J Hum Genet. 2014 Mar 6;94(3):415-25
pubmed: 24581740
Am J Hum Genet. 2015 Aug 6;97(2):199-215
pubmed: 26166479
Genet Med. 2016 Jul;18(7):696-704
pubmed: 26633542
N Engl J Med. 2017 Jan 5;376(1):21-31
pubmed: 27959697
Hum Mutat. 2017 May;38(5):517-523
pubmed: 28229513
Genet Med. 2017 Feb;19(2):224-235
pubmed: 27513193
Clin Genet. 2016 Mar;89(3):275-84
pubmed: 26283276
Hum Mutat. 2017 May;38(5):600-608
pubmed: 28106320
N Engl J Med. 2013 Oct 17;369(16):1502-11
pubmed: 24088041
Genet Med. 2015 Jul;17(7):578-86
pubmed: 25356970
Genet Med. 2014 Nov;16(11):830-7
pubmed: 24763289
Genet Med. 2017 Feb;19(2):209-214
pubmed: 27441994
Am J Med Genet A. 2017 Sep;173(9):2451-2455
pubmed: 28631899
Genome Med. 2017 Nov 27;9(1):101
pubmed: 29179772
Genet Med. 2018 Dec;20(12):1528-1537
pubmed: 29790871
Genet Med. 2014 Sep;16(9):717-9
pubmed: 24525916
JAMA. 2014 Nov 12;312(18):1870-9
pubmed: 25326635
Eur J Hum Genet. 2017 Feb;25(2):176-182
pubmed: 27848944
Nature. 2017 Feb 23;542(7642):433-438
pubmed: 28135719
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Clin Genet. 2017 Sep;92(3):281-289
pubmed: 28170084
Hum Genet. 2015 Sep;134(9):967-80
pubmed: 26077850
Genet Med. 2014 May;16(5):395-9
pubmed: 24113345
JAMA. 2014 Nov 12;312(18):1880-7
pubmed: 25326637
Nat Rev Genet. 2012 Jul 18;13(8):565-75
pubmed: 22805709
J Hum Genet. 2016 Feb;61(2):173-5
pubmed: 26490185
J Clin Invest. 2016 Feb;126(2):762-78
pubmed: 26752647

Auteurs

Erica D Smith (ED)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Kirsten Blanco (K)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Samin A Sajan (SA)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Jesse M Hunter (JM)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Deepali N Shinde (DN)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Bess Wayburn (B)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Mari Rossi (M)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Jennifer Huang (J)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Cathy A Stevens (CA)

Children's Hospital at Erlanger, Chattanooga, TN, USA.

Candace Muss (C)

Children's Hospital at Erlanger, Chattanooga, TN, USA.

Wendy Alcaraz (W)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Kelly D Farwell Hagman (KDF)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Sha Tang (S)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA.

Kelly Radtke (K)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA, USA. kradtke@ambrygen.com.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH